Laboratory of Abdominal Transplantation, Department of Microbiology, Immunology and Transplantation, Faculty of Medicine, KU Leuven, Leuven, Belgium.
University Hospital of Liège, Liège, Belgium.
Transpl Int. 2023 Nov 10;36:11947. doi: 10.3389/ti.2023.11947. eCollection 2023.
Organ preservation and assessment with machine perfusion (MP) has provided transplant physicians with the ability to evaluate and select grafts suitable for transplantation. Nevertheless, the discard of organs considered too damaged still sustains the imbalance between donor organs supply and demands. Therefore, there is the pressing clinical need for strategies to repair and/or regenerate organs before transplantation, and MP is uniquely positioned to satisfy this need. The systemic administration of mesenchymal stromal cells (MSC) was shown to reduce ischemia-reperfusion injury in pre-clinical organ transplant models but could not be reproduced in clinical transplantation, largely because of inefficient cell delivery. The administration of MSC during MP is one strategy that recently gained much attention as an alternative delivery method to target MSC directly to the donor organ. However, careful reinterpretation of preliminary results reveals that this approach is equally limited by a suboptimal delivery of short-lived MSC to the target organ. In contrast, the use of MSC secretome and/or extracellular vesicles therapy during MP seems to be more efficient in harnessing MSC properties during MP. In this mini review we speculate on the future of the novel niche of organ repair and regeneration before transplantation.
器官保存和评估的机器灌注(MP)为移植医生提供了评估和选择适合移植的移植物的能力。然而,由于考虑到器官受损太严重而被丢弃,仍然维持着供体器官供应和需求之间的不平衡。因此,迫切需要在移植前修复和/或再生器官的策略,而 MP 正是满足这一需求的独特位置。间充质基质细胞(MSC)的系统给药已被证明可以减少临床前器官移植模型中的缺血再灌注损伤,但在临床移植中无法重现,这主要是因为细胞传递效率低下。在 MP 期间给予 MSC 是一种最近备受关注的替代给药方法,可将 MSC 直接靶向供体器官。然而,对初步结果的仔细重新解释表明,这种方法同样受到将短暂 MSC 输送到目标器官的不理想的限制。相比之下,在 MP 期间使用 MSC 分泌组和/或细胞外囊泡治疗似乎更有效地利用了 MP 期间 MSC 的特性。在这篇迷你综述中,我们推测了移植前器官修复和再生的新领域的未来。